Clinical Trial Update: Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating add-on timolol for paronychia induced by EGFR-TKI and ALK-TKI therapies; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paronychia

Drugs mentioned

• Timolol (timolol)

Snippet

Sponsor: Queen Mary Hospital, Hong Kong | Conditions: Paronychia, EGFR-TKI | Phase 3 | Status: RECRUITING